Bridget Ross Appointed New CEO at ChroniSense Medical

“We are pleased Bridget Ross will bring her talents to ChroniSense as CEO,” said Ilan Neugarten, Chairman of the Board of Rainbow Medical, ChroniSense Medical’s largest investor. “We are confident Bridget’s extensive and diverse leadership experience will deliver impactful healthcare solutions to patients and will drive ChroniSense to a leading position in the disease management space.”

Bridget Ross brings more than three decades of strategic, operational and leadership expertise. Prior to joining ChroniSense, she was President of the Global Medical Group at Henry Schein and a member of the company’s Executive Management Committee. There, she led the growth strategy for a $2.4B global medical distribution, solutions and services business, and delivered revenue growth double the industry average.  Before joining Henry Schein,

Bridget Ross served as Vice President, Commercial Operations, Johnson & Johnson (J&J) Medical Device Sector. In this role, she led a commercial operations integration for the ~$12B NA Medical Device business and was instrumental in driving operational efficiencies. Previously, Ms. Ross held multiple executive roles, including Global President at two J&J subsidiaries in the Women’s Health & Urology and Otolaryngology spaces, where she was responsible for the development pipeline and commercialization of multiple innovative products.

“I am delighted to join ChroniSense,” Ms. Bridget Ross said. “The company’s breakthrough technology has the potential to be transformative for patients – a true game-changer in the digital health segment. I’m excited and honored to join the dedicated team at ChroniSense to work toward bringing meaningful benefits to patients, caregivers and shareholders alike.”

“We are excited about the potential for our technology to have an even greater impact on the lives of patients, and we are looking forward to a successful journey with Bridget’s leadership,” said Danny Lange, Founder, President and Director ChroniSense Labs Israel.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version